News stories about Ligand Pharmaceuticals (NASDAQ:LGND) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.7554133987361 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
LGND has been the subject of several research reports. Craig Hallum boosted their price objective on shares of Ligand Pharmaceuticals from $170.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Zacks Investment Research raised shares of Ligand Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 20th. HC Wainwright boosted their price objective on shares of Ligand Pharmaceuticals from $170.00 to $182.00 and gave the company a “buy” rating in a report on Wednesday, March 7th. ValuEngine raised shares of Ligand Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, TheStreet cut shares of Ligand Pharmaceuticals from a “b” rating to a “c+” rating in a report on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $161.00.
Shares of LGND stock opened at $192.23 on Friday. Ligand Pharmaceuticals has a 12 month low of $107.64 and a 12 month high of $196.56. The company has a market cap of $3.98 billion, a price-to-earnings ratio of 74.80, a price-to-earnings-growth ratio of 1.73 and a beta of 0.92. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.41 and a quick ratio of 1.37.
In other Ligand Pharmaceuticals news, Director John L. Lamattina sold 3,335 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $160.90, for a total transaction of $536,601.50. Following the completion of the sale, the director now directly owns 24,291 shares of the company’s stock, valued at $3,908,421.90. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Stephen L. Sabba sold 622 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $180.73, for a total transaction of $112,414.06. Following the sale, the director now directly owns 26,363 shares of the company’s stock, valued at $4,764,584.99. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,243 shares of company stock valued at $6,089,315. 8.30% of the stock is owned by corporate insiders.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.